ArticleJACC. Case reports2026
Full Body Embolic Protection During Transcatheter Aortic Valve Replacement in High Risk Patients.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stroke remains one of the most feared complications of transcatheter aortic valve replacement (TAVR). We report our initial experience using a dedicated full-body embolic protection device during TAVR in 3 patients with severe aortic stenosis and high-risk embolic features. This included large thrombus on the aortic valve, a left ventricular outflow tract mass, and persistent left atrial thrombus despite anticoagulation. Device deployment and retrieval were successful in all procedures, with no device-related complications or neurologic events at 30-day follow-up. Macroscopic debris was retrieved in 2 patients, and histopathologic analysis in 1 case demonstrated atheromatous plaque components. This initial experience demonstrates the feasibility of full-body embolic protection in selected patients with high-risk undergoing TAVR and supports further evaluation in prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.